Haemonetics earnings were $103.9M for the trailing 12 months ending Sep 26, 2026, with -33.1% growth year over year. The latest HAE earnings report on Sep 26, 2026 announced Q3 2026 earnings of $46.3M, up 40.3% from last quarter. For the last reported fiscal year 2026 ending Mar 28, 2026, HAE reported annual earnings of $97.3M, with -42% growth.
HAE past earnings growth
How has HAE's earnings growth performed historically?
On HAE's earnings call on Nov 5, 2026, Haemonetics (NYSE: HAE) reported Q3 2026 earnings per share (EPS) of $1.02, up 25.93% year over year. Total HAE earnings for the quarter were $46.31 million. In the same quarter last year, Haemonetics's earnings per share (EPS) was $0.81.
As of the last Haemonetics earnings report, Haemonetics is currently profitable. Haemonetics's net profit (also called net income) for the twelve months ending Sep 26, 2026 was $103.91 million, a 38.22% decrease year over year.
What was HAE's earnings growth in the past year?
As of Haemonetics's earnings date in Nov 5, 2026, Haemonetics's earnings has grown -33.14% year over year. This is 70.27 percentage points lower than the US Medical Instruments & Supplies industry earnings growth rate of 37.13%. HAE earnings in the past year totalled $103.91 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.